Visão geral da empresa
DBV Technologies S.A. operates as a clinical-stage biopharmaceutical company dedicated to the research and development of epicutaneous immunotherapy products, with its primary focus situated in France. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning itself as an entity focused on advancing therapeutic solutions for allergic conditions through innovative product pipelines. The current scale of the organization is reflected by a market capitalization of $1.27B and trailing twelve-month revenue of $5.64M, while the specific employee count is listed as N/A in available records. These valuation figures indicate that the market assigns a significant premium to the company's potential, suggesting that the biotechnology sector values the firm's pipeline assets and intellectual property heavily despite the current revenue base being relatively small compared to its market cap.
Saúde financeira
The financial statements for the trailing twelve months reveal a revenue of $5.64M, a net income of $-146,947,008, and an EBITDA of $-143,862,000, highlighting a substantial gap between top-line revenue generation and bottom-line profitability. This discrepancy illustrates an aggressive cost structure typical of clinical-stage companies, where research and development expenditures significantly outpace revenue, resulting in a negative profit margin of 0.0%. The company's free cash flow stands at $-64,285,000, which indicates that the business is currently burning cash to fund its operations and development activities rather than generating liquidity for distribution. Margins further reflect this operational reality, with a gross margin of 100.0% suggesting direct costs are fully offset by revenue on a gross basis, while the operating margin is reported at -6984.7%, signaling extreme operating inefficiency relative to current sales levels. In terms of leverage, the company holds $194.17M in cash against $6.53M in debt, supported by a debt-to-equity ratio of 3.87, which presents a complex balance sheet picture given the high leverage ratio but strong liquidity coverage. The current ratio of 3.67 demonstrates robust short-term liquidity, indicating that the company possesses more than three times the current assets necessary to cover its current liabilities. Return metrics show a Return on Equity of -149.8% and a Return on Assets of -61.4%, which reveals that management has not yet achieved profitability and that equity and assets are currently being utilized to generate losses rather than positive returns.
Avaliação de valorização
Valuation multiples present a distinct divergence due to the lack of normalized earnings, with a trailing P/E Ratio (TTM) listed as N/A and a forward P/E of -81.44, implying that the market is pricing the stock based on future expected earnings rather than historical performance. The price-to-book ratio is recorded at 6.01, indicating that the market values the company at more than six times its book value, which suggests a high premium assigned to the company's intangible assets and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 225.87 and an EV/EBITDA of -33.92 further emphasize that traditional earnings-based valuation models are not applicable, pointing instead to a reliance on revenue multiples and asset value. Regarding price volatility, the stock has a 52-week high of $26.18 and a 52-week low of $6.69, meaning the current trading price sits significantly below the 52-week high while being well above the 52-week low. The beta value is -0.20, which is an anomalous figure indicating a negative correlation to the broader market, suggesting that the stock's price movements may move inversely to market indices during specific periods.
Growth & Income
The company exhibits a revenue growth rate of 26.2% year-over-year, whereas earnings growth is N/A, illustrating that top-line expansion is occurring while profitability remains nonexistent due to the heavy costs associated with clinical development. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available cash flow is being retained and reinvested into the business rather than distributed to shareholders. The absence of a dividend payout is consistent with the company's life-stage, where capital is directed toward advancing the Viaskin Peanut product and completing Phase 3 clinical trials for treatment indications. Overall, the growth and income profile is characterized by rapid revenue expansion coupled with negative earnings, typical of a clinical-stage biotechnology firm prioritizing asset development over immediate shareholder returns.